Ovensa is a Canadian preclinical stage company developing a siRNA drug candidate silencing the overexpression of galectin-1 in the tumor microenvironment to improve therapeutic outcomes of immuno-oncology checkpoint inhibitors and other cancer drugs.

Ovensa works with pharmaceutical companies to develop precision and combination medicines using its non-viral and non-lipidic TRIOZAN™ drug delivery platform.

The company is currently raising a 15MM USD Series A to advance its siRNA into the clinic.

 OVENSA logo



Event details

Date: September 14 - 16, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


16 in total